Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis (vol 9, ofac637, 2022)

A. Savinkina,A. D. Paltiel,S. J. Ross,G. Gonsalves

Open forum infectious diseases（2023）

引用 3|浏览6

暂无评分

摘要

Priority for nirmatrelvir/ritonavir treatment should be given to unvaccinated persons at high risk of severe disease from COVID-19. Further priority may be assigned by weighing treatment effectiveness, disease severity, drug cost, and willingness to pay for deaths averted.

查看译文

关键词

COVID-19,allocation,cost-effectiveness,nirmatrelvir/ritonavir

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要